Tirzepatide is a medication developed to treat type 2 diabetes and obesity. It is a dual agonist, meaning it activates two different receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)receptors. These receptors play critical roles in regulating blood sugar and metabolism.
Tirzepatide improves blood sugar control by:
- Increasing insulin secretion when blood sugar levels are high
- Suppressing glucagon release, which helps reduce glucose production in the liver
- Slowing gastric emptying, leading to reduced appetite and enhanced feelings of fullness
This dual mechanism can provide better glycemic control and weight loss compared to medications targeting only the GLP-1 receptor.